Cairn Diagnostics

Cairn Diagnostics is a U.S.-based diagnostics company that has commercialized the first FDA-approved at-home breath test for gastroparesis, the Gastric Emptying Breath Test (GEBT). This test provides a non-radioactive, convenient alternative to the traditional scintigraphy test, which requires a hospital visit and exposure to trace radiation. The company targets the over 5 million patients suffering from gastroparesis, with a particular focus on diabetics, and leverages telehealth for test administration. Cairn operates as a commercial-stage, private company offering a direct diagnostic solution.

Non-radioactive stable isotope (13C) breath testing platform for measuring gastric emptying and potentially other gastrointestinal functions.

Primary competition comes from the entrenched gold standard, gastric emptying scintigraphy, performed in hospital nuclear medicine departments. Other competitors may include wireless motility capsule systems (e.g., SmartPill) and emerging MRI-based techniques. Cairn's GEBT differentiates through its at-home capability, lack of radiation, and standardized protocol.